Supply of Medicine and Medical / Surgical equipments : Dried Factor IX Fraction 500 IU-600IU vial\nConcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur, 500IU\n- 600IU\nEach vial to contain 500 IU - 600IU of\nconcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur. The\nproduct containing alternate number of\nUnits/vial also will be considered.\nNote:\n1. Item must include an effective viral\ninactivation steps to ensure that the product is\nsafer for infusions(viral inactivation steps must\nbe given in details)\n2. Date of expiry of the item should be at least\n02 years ahead from the date of receipt of the\nproduct in Sri Lanka.\n3. Tenderer should submit detailed\nspecifications of the product offered.\n4. The product should ensure, at least two\nsteps on virus inactivation as recommended by\nWHO/US.FDA\n5. The donor selection process should be\nspecified by the manufacturer.\n6. Each batch should be certified as free from\nHIV and hepatitis viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared\nby the manufacturer. The test methods used\nshould be approved by WHO/US.FDA.\n8. The product should be protected from light.\nPacking : One vial etc .

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA Sri Lanka has Released a tender for Supply of Medicine and Medical / Surgical equipments : Dried Factor IX Fraction 500 IU-600IU vial\nConcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur, 500IU\n- 600IU\nEach vial to contain 500 IU - 600IU of\nconcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur. The\nproduct containing alternate number of\nUnits/vial also will be considered.\nNote:\n1. Item must include an effective viral\ninactivation steps to ensure that the product is\nsafer for infusions(viral inactivation steps must\nbe given in details)\n2. Date of expiry of the item should be at least\n02 years ahead from the date of receipt of the\nproduct in Sri Lanka.\n3. Tenderer should submit detailed\nspecifications of the product offered.\n4. The product should ensure, at least two\nsteps on virus inactivation as recommended by\nWHO/US.FDA\n5. The donor selection process should be\nspecified by the manufacturer.\n6. Each batch should be certified as free from\nHIV and hepatitis viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared\nby the manufacturer. The test methods used\nshould be approved by WHO/US.FDA.\n8. The product should be protected from light.\nPacking : One vial etc . in Pharmaceuticals. The tender was released on Mar 20, 2025.

Country - Sri Lanka

Summary - Supply of Medicine and Medical / Surgical equipments : Dried Factor IX Fraction 500 IU-600IU vial\nConcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur, 500IU\n- 600IU\nEach vial to contain 500 IU - 600IU of\nconcentrated, monoclonal,purified and\nDetergent treated Dried factor IX Fraction BP\nor Human Coagulation Factor IX Ph Eur. The\nproduct containing alternate number of\nUnits/vial also will be considered.\nNote:\n1. Item must include an effective viral\ninactivation steps to ensure that the product is\nsafer for infusions(viral inactivation steps must\nbe given in details)\n2. Date of expiry of the item should be at least\n02 years ahead from the date of receipt of the\nproduct in Sri Lanka.\n3. Tenderer should submit detailed\nspecifications of the product offered.\n4. The product should ensure, at least two\nsteps on virus inactivation as recommended by\nWHO/US.FDA\n5. The donor selection process should be\nspecified by the manufacturer.\n6. Each batch should be certified as free from\nHIV and hepatitis viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared\nby the manufacturer. The test methods used\nshould be approved by WHO/US.FDA.\n8. The product should be protected from light.\nPacking : One vial etc .

Deadline - Apr 30, 2025

MT reference number - 105339270

Product classification - Pharmaceutical products